Patents by Inventor Christopher Malcuit

Christopher Malcuit has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220049217
    Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells am molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described hemin are useful for treating retinal degenerative diseases.
    Type: Application
    Filed: March 29, 2021
    Publication date: February 17, 2022
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20210060062
    Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.
    Type: Application
    Filed: October 9, 2019
    Publication date: March 4, 2021
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20200113938
    Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.
    Type: Application
    Filed: October 9, 2019
    Publication date: April 16, 2020
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20200016297
    Abstract: The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides.
    Type: Application
    Filed: September 27, 2019
    Publication date: January 16, 2020
    Applicant: Worcester Polytechnic Institute
    Inventors: Marsha Rolle, Fioleda Prifti, Christopher Malcuit, Terri Anne Camesano, Tanja Dominko, Denis Kole, Destin Heilman
  • Patent number: 10485829
    Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: November 26, 2019
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Patent number: 10449271
    Abstract: The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides.
    Type: Grant
    Filed: April 2, 2018
    Date of Patent: October 22, 2019
    Assignee: Worcester Polytechnic Institute
    Inventors: Marsha Rolle, Fioleda Prifti, Christopher Malcuit, Terri Anne Camesano, Tanja Dominko, Denis Kole
  • Publication number: 20190062703
    Abstract: The present invention provides improved methods For producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.
    Type: Application
    Filed: August 27, 2018
    Publication date: February 28, 2019
    Applicant: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20180280579
    Abstract: The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides.
    Type: Application
    Filed: April 2, 2018
    Publication date: October 4, 2018
    Inventors: Marsha Rolle, Fioleda Prifti, Christopher Malcuit, Terri Anne Camesano, Tanja Dominko, Denis Kole
  • Patent number: 10077424
    Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.
    Type: Grant
    Filed: April 16, 2014
    Date of Patent: September 18, 2018
    Assignee: Astellas Institute for Regenerative Medicine
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Patent number: 9931437
    Abstract: The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: April 3, 2018
    Assignee: WORCESTER POLYTECHNIC INSTITUTE
    Inventors: Marsha Rolle, Fioleda Prifti, Christopher Malcuit, Terri Anne Camesano, Tanja Dominko, Denis Kole
  • Publication number: 20150202350
    Abstract: The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides.
    Type: Application
    Filed: February 4, 2015
    Publication date: July 23, 2015
    Inventors: Marsha Rolle, Fioleda Prifti, Christopher Malcuit, Terri Anne Camesano, Tanja Dominko, Denis Kole
  • Publication number: 20150086512
    Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.
    Type: Application
    Filed: April 16, 2014
    Publication date: March 26, 2015
    Applicant: Advanced Cell Technology, Inc.
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20130149284
    Abstract: The present invention provides improved methods for producing retinal pigmented epithelial (RPE) cells from human embryonic stem cells, human induced pluripotent stem (iPS), human adult stem cells, human hematopoietic stem cells, human fetal stem cells, human mesenchymal stem cells, human postpartum stem cells, human multipotent stem cells, or human embryonic germ cells. The RPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The RPE cells described herein are useful for treating retinal degenerative conditions including retinal detachment and macular degeneration.
    Type: Application
    Filed: November 17, 2010
    Publication date: June 13, 2013
    Applicant: Advanced Cell Technlogy, Inc.
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20130095078
    Abstract: An engineered muscle construct in the form of a braided collagen microthread scaffold is provided. The microthread scaffold can be used with or without cells as engineered skeletal muscle. The microthread scaffold can also be used to promote cell attachment and growth to deliver cells to a large muscle defect to stimulate muscle regeneration. Methods for making a muscle construct, seeding cells onto microthread scaffolds and treating muscle defects are also provided.
    Type: Application
    Filed: March 11, 2011
    Publication date: April 18, 2013
    Inventors: Christopher Malcuit, Tanja Dominko, Raymond Lynn Page, George D. Pins, Jennifer Makridakis
  • Publication number: 20110286978
    Abstract: The present disclosure relates to methods for dedifferentiating and transdifferentiating recipient cells, preferably human somatic cells. These methods minimize the risk of undesired genome sequence alteration. These methods employ reprogramming factors, which may be used alone or in certain combinations with one another. These methods have application especially in the context of cell-based therapies, establishment of cell lines, and the production of genetically modified cells.
    Type: Application
    Filed: May 25, 2010
    Publication date: November 24, 2011
    Inventors: Irina V. Klimanskaya, Shi-Jiang Lu, Robert Lanza, Michael D. West, Karen B. Chapman, Roy Geoffrey Sargent, Raymond Page, Tanja Dominko, Christopher Malcuit
  • Publication number: 20110274662
    Abstract: The present invention provides improved methods for producing RPE cells from human embryonic stem cells or from other human pluripotent stem cells. The invention also relates to human retinal pigmented epithelial cells derived from human embryonic stem cells or other human multipotent or pluripotent stem cells. hRPE cells derived from embryonic stem cells are molecularly distinct from adult and fetal-derived RPE cells, and are also distinct from embryonic stem cells. The hRPE cells described herein are useful for treating retinal degenerative diseases.
    Type: Application
    Filed: October 10, 2008
    Publication date: November 10, 2011
    Inventors: Christopher Malcuit, Linda Lemieux, William Holmes, Pedro Huertas, Lucy Vilner
  • Publication number: 20110171185
    Abstract: The present disclosure relates to methods for dedifferentiating and transdifferentiating recipient cells, preferably human somatic cells. These methods minimize the risk of undesired genome sequence alteration. These methods employ reprogramming factors, which may be used alone or in certain combinations with one another. These methods have application especially in the context of cell-based therapies, establishment of cell lines, and the production of genetically modified cells.
    Type: Application
    Filed: February 4, 2010
    Publication date: July 14, 2011
    Inventors: IRINA V. KLIMANSKAYA, SHI-JIANG LU, ROBERT LANZA, MICHAEL D. WEST, KAREN B. CHAPMAN, ROY GEOFFREY SARGENT, RAYMOND PAGE, TANJA DOMINKO, CHRISTOPHER MALCUIT
  • Publication number: 20100120079
    Abstract: The invention provides a method for effecting the trans-differentiation of a somatic cell, i.e., the conversion of a somatic cell of one cell type into a somatic cell of a different cell type. The method is practiced by culturing a somatic cell in the presence of at least one agent selected from the group consisting of (a) cytoskeletal inhibitors and (b) inhibitors of acetylation, and (c) inhibitors of methylation, and also culturing the cell in the presence of agents or conditions that induce differentiation to a different cell type. The method is useful for producing histocompatible cells for cell therapy.
    Type: Application
    Filed: October 30, 2009
    Publication date: May 13, 2010
    Inventors: Raymond Page, Tanja Dominko, Christopher Malcuit
  • Patent number: 7621606
    Abstract: The invention provides a method for effecting the trans-differentiation of a somatic cell, i.e., the conversion of a somatic cell of one cell type into a somatic cell of a different cell type. The method is practiced by culturing a somatic cell in the presence of at least one agent selected from the group consisting of (a) cytoskeletal inhibitors and (b) inhibitors of acetylation, and (c) inhibitors of methylation, and also culturing the cell in the presence of agents or conditions that induce differentiation to a different cell type. The method is useful for producing histocompatible cells for cell therapy.
    Type: Grant
    Filed: August 27, 2002
    Date of Patent: November 24, 2009
    Assignee: Advanced Cell Technology, Inc.
    Inventors: Raymond Page, Tanja Dominko, Christopher Malcuit
  • Publication number: 20030059939
    Abstract: The invention provides a method for effecting the trans-differentiation of a somatic cell, i.e., the conversion of a somatic cell of one cell type into a somatic cell of a different cell type. The method is practiced by culturing a somatic cell in the presence of at least one agent selected from the group consisting of (a) cytoskeletal inhibitors and (b) inhibitors of acetylation, and (c) inhibitors of methylation, and also culturing the cell in the presence of agents or conditions that induce differentiation to a different cell type. The method is useful for producing histocompatible cells for cell therapy.
    Type: Application
    Filed: August 27, 2002
    Publication date: March 27, 2003
    Inventors: Raymond Page, Tanja Dominko, Christopher Malcuit